$0.23
Revenue is down for the last 2 quarters, 37.70M → 12.53M (in $), with an average decrease of 66.8% per quarter
Netprofit is up for the last 2 quarters, -22.78M → -13.44M (in $), with an average increase of 69.5% per quarter
In the last 1 year, Minerva Surgical Inc has experienced a drawdown of -90.8%, however 10x Genomics Inc - Class A resisted the overall trend and outperformed by 90.3%
4.74%
Downside
Day's Volatility :10.57%
Upside
6.12%
34.83%
Downside
52 Weeks Volatility :95.04%
Upside
92.38%
Period | MINERVA SURGICAL, INC. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -22.74% | 0.3% | -6.7% |
6 Months | 23.99% | -6.1% | -3.7% |
1 Year | -90.38% | -4.8% | -6.3% |
3 Years | -97.44% | 23.8% | 26.9% |
Market Capitalization | 44.6M |
Book Value | $0.19 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.93 |
Wall Street Target Price | 1.0 |
Profit Margin | -66.54% |
Operating Margin TTM | -76.8% |
Return On Assets TTM | -26.83% |
Return On Equity TTM | -100.36% |
Revenue TTM | 51.9M |
Revenue Per Share TTM | 1.13 |
Quarterly Revenue Growth YOY | 14.6% |
Gross Profit TTM | 27.2M |
EBITDA | -29.2M |
Diluted Eps TTM | -0.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.37 |
EPS Estimate Next Year | -0.31 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.09 |
What analysts predicted
Upside of 334.78%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 26.0M | - |
Net Income | -52.0M | - |
Net Profit Margin | -200.08% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 37.8M | ↑ 45.19% |
Net Income | -18.3M | ↓ 64.91% |
Net Profit Margin | -48.36% | ↑ 151.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 52.1M | ↑ 37.96% |
Net Income | -21.5M | ↑ 17.53% |
Net Profit Margin | -41.2% | ↑ 7.16% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 50.3M | ↓ 3.47% |
Net Income | -34.1M | ↑ 58.93% |
Net Profit Margin | -67.83% | ↓ 26.63% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 13.6M | ↑ 9.11% |
Net Income | 10.8M | ↓ 435.13% |
Net Profit Margin | 79.21% | ↑ 105.0% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 10.9M | ↓ 19.86% |
Net Income | -10.9M | ↓ 201.08% |
Net Profit Margin | -99.91% | ↓ 179.12% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.0M | ↑ 18.58% |
Net Income | -5.6M | ↓ 48.62% |
Net Profit Margin | -43.29% | ↑ 56.62% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 12.6M | ↓ 2.92% |
Net Income | -11.3M | ↑ 101.84% |
Net Profit Margin | -90.0% | ↓ 46.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 37.7M | ↑ 199.54% |
Net Income | -22.8M | ↑ 101.1% |
Net Profit Margin | -60.42% | ↑ 29.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.5M | ↓ 66.76% |
Net Income | -13.4M | ↓ 40.99% |
Net Profit Margin | -107.27% | ↓ 46.85% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 46.7M | - |
Total Liabilities | 251.2M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 92.0M | ↑ 97.17% |
Total Liabilities | 313.9M | ↑ 24.94% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 115.1M | ↑ 25.04% |
Total Liabilities | 71.0M | ↓ 77.38% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 68.9M | ↓ 40.13% |
Total Liabilities | 51.7M | ↓ 27.14% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 115.1M | ↑ 41.76% |
Total Liabilities | 71.0M | ↓ 78.39% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 100.5M | ↓ 12.68% |
Total Liabilities | 65.8M | ↓ 7.37% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 94.0M | ↓ 6.51% |
Total Liabilities | 63.1M | ↓ 4.03% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 83.8M | ↓ 10.81% |
Total Liabilities | 62.3M | ↓ 1.33% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 68.9M | ↓ 17.78% |
Total Liabilities | 51.7M | ↓ 16.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 85.2M | ↑ 23.61% |
Total Liabilities | 51.1M | ↓ 1.2% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -19.8M | - |
Investing Cash Flow | -223.0K | - |
Financing Cash Flow | 43.2M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.2M | ↓ 38.15% |
Investing Cash Flow | -15.5M | ↑ 6829.6% |
Financing Cash Flow | 18.1M | ↓ 58.11% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.4M | ↑ 82.82% |
Investing Cash Flow | -25.6M | ↑ 65.56% |
Financing Cash Flow | 71.2M | ↑ 293.94% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.3M | ↑ 237.18% |
Investing Cash Flow | -24.7M | ↑ 5967.81% |
Financing Cash Flow | 46.2M | ↑ 124697.3% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.6M | ↓ 55.82% |
Investing Cash Flow | -82.0K | ↓ 99.67% |
Financing Cash Flow | -5.0M | ↓ 110.82% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.5M | ↓ 27.93% |
Investing Cash Flow | -41.0K | ↓ 50.0% |
Financing Cash Flow | 18.0K | ↓ 100.36% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.8M | ↑ 23.8% |
Investing Cash Flow | -2.0K | ↓ 95.12% |
Financing Cash Flow | 13.0K | ↓ 27.78% |
Sell
Neutral
Buy
MINERVA SURGICAL, INC. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() MINERVA SURGICAL, INC. | -8.04% | 23.99% | -90.38% | -97.44% | -97.44% |
![]() R1 RCM Inc | 3.35% | 94.67% | -25.2% | 51.37% | 101.76% |
![]() 10X Genomics Inc | 0.61% | 50.7% | 3.01% | -32.37% | -0.04% |
![]() Veeva Systems Inc. | -8.07% | -9.3% | -2.81% | -24.39% | 118.28% |
![]() GE HEALTHCARE TECHNOLOGIES INC. | -2.58% | 30.1% | 30.1% | 30.1% | 30.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() MINERVA SURGICAL, INC. | NA | NA | NA | -0.37 | -1.0 | -0.27 | 0.0 | 0.19 |
![]() R1 RCM Inc | 128.18 | NA | 0.77 | 0.04 | -0.06 | 0.04 | 0.0 | 6.5 |
![]() 10X Genomics Inc | NA | NA | NA | -1.42 | -0.22 | -0.11 | 0.0 | 6.91 |
![]() Veeva Systems Inc. | 54.75 | 54.75 | 1.27 | 4.18 | 0.15 | 0.07 | 0.0 | 23.48 |
![]() GE HEALTHCARE TECHNOLOGIES INC. | 21.41 | 21.41 | NA | 3.73 | 0.16 | 0.06 | 0.0 | 14.72 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() MINERVA SURGICAL, INC. | Buy | $44.6M | -97.44% | NA | -66.54% |
![]() R1 RCM Inc | Buy | $7.0B | 101.76% | 128.18 | -4.41% |
![]() 10X Genomics Inc | Buy | $6.0B | -0.04% | NA | -32.51% |
![]() Veeva Systems Inc. | Buy | $26.0B | 118.28% | 54.75 | 22.63% |
![]() GE HEALTHCARE TECHNOLOGIES INC. | Buy | $36.3B | 30.1% | 21.41 | 9.17% |
NEA Management Company, LLC
Vivo Capital, LLC
Versant Venture Management LLC
Awm Investment Company Inc
Bridgeway Capital Management, LLC
UBS Group AG
MINERVA SURGICAL, INC.’s price-to-earnings ratio stands at None
Read MoreOrganization | MINERVA SURGICAL, INC. |
Employees | 174 |
CEO | Mr. David M. Clapper |
Industry | Healthcare |